PMID- 36636092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230115
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 13
IP  - 6
DP  - 2022 Dec
TI  - Gelatin sponge microparticles for transarterial chemoembolization combined with 
      regorafenib in hepatocellular carcinoma: a single-center retrospective study.
PG  - 3183-3192
LID - 10.21037/jgo-22-1170 [doi]
AB  - BACKGROUND: The treatment of advanced hepatocellular carcinoma (HCC) is 
      challenging. The positive effect of gelatin sponge microparticles for 
      transarterial chemoembolization (GSMs-TACE) in the treatment of Barcelona Clinic 
      Liver Cancer (BCLC) stage C and large HCC has been confirmed by previous studies. 
      This study initially explored the efficacy and safety of GSMs-TACE combined with 
      regorafenib in patients with unresectable HCC who failed first-line sorafenib 
      and/or lenvatinib therapy. METHODS: This retrospective study collated the data of 
      patients who presented at the Affiliated Zhongshan Hospital of Dalian University 
      between December 2018 and June 2021. Patients were treated with GSMs-TACE, 
      followed by regorafenib 1 week later. Follow-up was conducted every 3 to 5 weeks 
      after combination therapy. If the treatment was changed due to disease 
      progression, the patients were followed up every 3 months to obtain overall 
      survival (OS) time. The OS, progression-free survival (PFS), objective response 
      rate (ORR) and disease control rate (DCR) was used to evaluate the efficacy of 
      the treatment, while adverse events (AEs) was used to assess its safety. RESULTS: 
      A total of 47 patients were included in the study. The age of patients was 
      64.4+/-6.8 years; There were 43 (91.5%) males and 4 (8.5%) females; the number of 
      Child-Pugh grade A was 22 (46.8%) and B was 25 (53.2%); the longest tumor 
      diameter was 5.1 cm [interquartile range (IQR), 3.8, 8.9 cm]; the number of BCLC 
      grade B was 14 (29.8%) and grade C was 33 (70.2%). The median follow-up time was 
      11.6 months [95% confidence interval (CI): 10.8 to 14.0 months]. The median 
      number of GSMS-TACE sessions was 3. The initial doses of regorafenib were 80 mg/d 
      (n=17, 36.2%), 120 mg/d (n=23, 48.9%), and 160 mg/d (n=7, 14.9%). The median PFS 
      was 6.0 months (95% CI: 4.5 to 7.5 months), and the median OS was 14.3 months 
      (95% CI: 11.8 to 16.8 months). The ORR and DCR were 21.3% and 85.1%, 
      respectively. The incidence of grade 3/4 AEs was 8 out of 47 patients (17.0%). 
      CONCLUSIONS: The study indicated that GSMs-TACE combined with regorafenib may be 
      efficient and safe in patients with unresectable HCC. Future prospective 
      large-scale studies should be conducted to verify these results.
CI  - 2022 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Su, Mao
AU  - Su M
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Chen, Songbai
AU  - Chen S
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Li, Shengmin
AU  - Li S
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Xu, Fang
AU  - Xu F
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Zhao, Guangsheng
AU  - Zhao G
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Qu, Junjie
AU  - Qu J
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Interventional Medicine Center, Affiliated Zhongshan Hospital of Dalian 
      University, Dalian, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC9830337
OTO - NOTNLM
OT  - Gelatin sponge microparticles
OT  - hepatocellular carcinoma (HCC)
OT  - regorafenib
OT  - transarterial chemoembolization
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://jgo.amegroups.com/article/view/10.21037/jgo-22-1170/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2023/01/14 06:00
MHDA- 2023/01/14 06:01
PMCR- 2022/12/01
CRDT- 2023/01/13 01:54
PHST- 2022/11/03 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2023/01/13 01:54 [entrez]
PHST- 2023/01/14 06:00 [pubmed]
PHST- 2023/01/14 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - jgo-13-06-3183 [pii]
AID - 10.21037/jgo-22-1170 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2022 Dec;13(6):3183-3192. doi: 10.21037/jgo-22-1170.